Philippe Clevenbergh
Impact in
- Virology top 0.5%
- HIV Research and Treatment
-
- Antibiotic Use and Resistance
Papers in
- Virology 26
- HIV Research and Treatment 24
-
- HIV/AIDS Research and Interventions 25
- HIV/AIDS drug development and treatment 21
- Tuberculosis Research and Epidemiology 4
- COVID-19 Clinical Research Studies 3
- Co-authors
- P. DellamonicaJ. DurantPhilippe HalfonN MontagneCAB BoucherPascal Del-GiudicePere SimonetR. Garraffo
- Journals
- Clinical Infectious Diseases (3 papers)JAIDS Journal of Acquired Immune Deficiency Syndromes (3 papers)AIDS (3 papers)HIV Clinical Trials (3 papers)Antiviral Therapy (3 papers)
- Partner nations
- FranceBelgiumUnited States
In The Last Decade
Philippe Clevenbergh
59 papers receiving 2.1k citations
Hit Papers
Peers
Comparison fields: 5 of 123
- Virology 1.0k
- Applied Microbiology and Biotechnology 258
- Infectious Diseases 1.4k
- Molecular Medicine 349
- Critical Care and Intensive Care Medicine 99
Countries citing papers authored by Philippe Clevenbergh
This map shows the geographic impact of Philippe Clevenbergh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Clevenbergh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Clevenbergh more than expected).
Fields of papers citing papers by Philippe Clevenbergh
This network shows the impact of papers produced by Philippe Clevenbergh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Clevenbergh. The network helps show where Philippe Clevenbergh may publish in the future.
Co-authors
The 25 scholars most cited alongside Philippe Clevenbergh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2024 | 2 | |
| 3 | 2023 | 3 | |
| 4 | 2022 | 2 | |
| 5 | 2021 | 27 | |
| 6 | 2021 | 0 | |
| 7 | 2020 | 19 | |
| 8 | Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial Hit paper breakdown → | 2020 | 319 |
| 9 | 2018 | 9 | |
| 10 | 2016 | 2 | |
| 11 | 2014 | 34 | |
| 12 | 2010 | 5 | |
| 13 | 2006 | 19 | |
| 14 | 2004 | 3 | |
| 15 | 2004 | 11 | |
| 16 | 2003 | 4 | |
| 17 | 2003 | 23 | |
| 18 | 2002 | 10 | |
| 19 | 2000 | 28 | |
| 20 | 1997 | 2 |
About Philippe Clevenbergh
Philippe Clevenbergh is a scholar working on Virology, Infectious Diseases, Applied Microbiology and Biotechnology, Endocrinology and Small Animals, having authored 63 papers that have together received 2.2k indexed citations. Recurring topics across this work include HIV/AIDS Research and Interventions (25 papers), HIV Research and Treatment (24 papers), HIV/AIDS drug development and treatment (21 papers), Streptococcal Infections and Treatments (4 papers), Tuberculosis Research and Epidemiology (4 papers), HIV, Drug Use, Sexual Risk (4 papers), COVID-19 Clinical Research Studies (3 papers) and Prion Diseases and Protein Misfolding (3 papers). The work is most often cited by research in Virology (1.0k citations), Applied Microbiology and Biotechnology (258 citations), Infectious Diseases (1.4k citations), Molecular Medicine (349 citations) and Critical Care and Intensive Care Medicine (99 citations). Philippe Clevenbergh has collaborated with scholars based in France, Belgium and United States. Frequent co-authors include P. Dellamonica, J. Durant, Philippe Halfon, N Montagne, CAB Boucher, Pascal Del-Giudice, Pere Simonet, R. Garraffo, Marc Struelens and P. Del Giudice. Their work appears in journals such as Clinical Infectious Diseases, JAIDS Journal of Acquired Immune Deficiency Syndromes, AIDS, HIV Clinical Trials and Antiviral Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.